BASi Names Philip A. Downing Vice President of Preclinical Services

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Bioanalytical Systems, Inc. (NASDAQ:BASI) today announced that Philip A. Downing has been promoted to Vice President, Preclinical Services.

"Since joining BASi in 1997, Philip has always maintained a high level of focus on our clients' needs throughout the full range of both GLP and non-GLP Preclinical and Nonclinical services including Discovery, PKPD, acute & chronic toxicology, DART, juvenile toxicology, and carcinogenicity studies supporting IND and NDA enabling programs offered at the BASi facility located near Evansville, IN. Under Philip's leadership, we will broaden our collaborative outreach and build on an already outstanding track record of supporting our clients' drug discovery and early-stage development efforts," said Jacqueline Lemke, President and Chief Executive Officer of BASi.

After receiving a B.A. in Chemistry and Biology from Indiana University in 1993, Mr. Downing worked for a clinical research laboratory, GFi Pharmaceuticals (now Covance Labs) as an Analytical Scientist designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. Philip has worked at BASi for 18 years, starting as an Analytical Chemist and earning responsibilities in more progressively influential leadership roles throughout his tenure.

This appointment continues to position BASi as the partner of choice for early-stage drug development and to enhance the Company's ability to meet the needs of its clients and to drive future growth.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

Contacts

Bioanalytical Systems, Inc.
Jeffrey Potrzebowski, Chief Financial Officer, 765-497-8409
[email protected]

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.